Trial Profile
An international, randomised, open label trial comparing a rituximab based regimen and a standard cyclophosphamide/azathioprine based regimen in the treatment of active 'generalised' ANCA associated vasculitis.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 28 Dec 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Azathioprine; Cyclophosphamide
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Granulomatosis with polyangiitis; Microscopic polyangiitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms RITUXVAS
- 16 May 2019 This trial has been completed as per European Clinical Trials Database record.